Study of Apremilast in Atopic or Contact Dermatitis

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Tufts Medical Center
Study ID
NCT00931242
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).

Study Details

The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.

Key Dates

First listed
Jul 2, 2009
Start date
Jun 30, 2009
Status verified
Nov 2010
Primary completion
Mar 31, 2010
Completion
Mar 31, 2010

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apremilast
    Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).

Primary Outcome Measure

Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Tufts Medical Center, Department of DermatologyBostonMassachusetts02111-

Find similar trials in Boston, MA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Tufts Medical Center, Department of Dermatology· Boston, MA

Related Studies